跳至主要内容
临床试验/NCT02689830
NCT02689830Unknown不适用

Prostate Embolization for Acute Urinary Retention Study (PARIS 1): An Open-label Prospective Study

ClinSearch6 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2016年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
ClinSearch
入组人数
20
试验地点
6
主要终点
Procedure success

研究概览

简要总结

The purpose of this study is to assess the feasibility and safety of Prostate Artery Embolization (PAE) in patients suffering of Acute Urinary Retention (AUR) in the context Benign Prostatic Hypertrophy (BPH).

详细描述

This is an open-label prospective, multicenter (centralized procedure), single arm, sequentially enrolling study. Twenty subjects will be enrolled in the study.

Patient will be referred by the attending urologists after failure of the currently recommended approach of Trial WithOut Catheter (TWOC) and alpha-adrenergic receptor (AR) blockers.

It is expected that all AUR cases referred to the local urological clinic will be considered for inclusion in the trial. A trial log book will be completed by the referring local urologist in order to obtain preliminary data on the applicability of the trial to all AUR comers in the institution. This log book will be limited to a very simple questionnaire to ensure high rate of completion by the attending resident/fellow (Patients age, size of prostate, previous Benign Prostate Hypertrophy symptoms, renal function). It will be used in order to assess the external validity of this first phase trial and will be a help to design the potential next step trial.

When a patient will present with AUR in the corresponding urological clinic, the PI and Clinical research coordinator will be informed by a short text message, fax or e-mail in order to prepare the following process.

Patient will be informed by the urologist of the ongoing research project. In summary, this will consist in informing the patient that the first step is TWOC and in case of failure of TWOC several options are offered including PAE in the trial setting. Inclusion of the patient will considered only in case of failure of TWOC.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • AUR Patients presenting with a first episode of AUR related to BPH (no matter if previously known or not) AND
  • Failure of at least one TWOC AND
  • Prostate size > or = 50 ml (ultrasound measurement)

排除标准

  • Known hypocontractile bladder
  • AUR related to other causes (Acute prostatitis or documented Prostate cancer)
  • Severe iodine allergy
  • Known prostate cancer
  • Known ongoing acute or chronic prostatitis
  • On-going acute pyelonephritis or septicemia from urinary origin
  • Patient refusing PAE
  • Severe renal failure (creatinine Clearance < 20 ml/min (MDRD)
  • Contra-indication to AR blockers (postural hypotension micturition syncope)
  • Contra-indication to anticoagulants
  • Patient catheterized with a suspubian catheter
  • Patient <18
  • Patients who are prisoners
  • Patients who are mentally incapacitated
  • Patients participating in an investigational study involving the peripheral vasculature
  • Patients unable or unwilling to provide written informed consent
  • Patients ineligible for pelvic angiography and embolization including severe atheromatous condition or any anatomical condition

研究组 & 干预措施

Bead Block microspheres

Experimental

Prostate embolization

干预措施: Bead Block (Device)

结局指标

主要结局

Procedure success

时间窗: 6 months after PAE

percentage of patients free of Foley and/or any prostate surgery

次要结局

  • Number of cumulated hospitalization days(between PAE and 6 months post-PAE)
  • Comparison of the number of Benign Prostate Hypertrophy medication(before and 6 months after PAE)
  • Percentage of procedure related or contributed complications(1 week after PAE)
  • Percentage of immediate technical success of embolization(5 minutes after the beginning of the procedure)
  • Comparison of International Prostate Symptom Score(between pre-PAE and 6 months post-PAE)
  • Comparison of Quality of Life Questionnaire(between pre-PAE and 6 months post-PAE)
  • Time of re-catheterization(6 months after PAE)
  • Time until TransUrethral Resection of the Prostate or open surgery(6 months)
  • Cumulative number of days with bladder catheter(between PAE and 6 months post-PAE)
  • Cumulative number of per-procedure angiographic and clinical complications(24 hours after PAE)
  • Comparison of International Index of Erectile Function(between pre-PAE and 6 months post-PAE)
  • Number of re-catheterization(6 months after PAE)
  • Total number of consultations(between PAE and 6 months post-PAE)
  • Immediate technical success of embolization(5 minutes after the beginning of the procedure)
  • Number of patients free of bladder catheter(between PAE and 6 months post-PAE)
  • Prostate volume(6 months)

研究者

发起方
ClinSearch
申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验